Date: 2012-09-05
Type of information: Fundraising
Company: F2G (UK)
Investors: Advent Life Sciences
Novartis Bioventures (Switzerland)
Sunstone Capital
Merifin Capital
K Nominees
Astellas Venture Fund
Amount: $30 Million (€ 23.75 million)
Funding type: financing round
Planned used: These funds will be used to select a clinical candidate from the F3 series of advanced preclinical analogs and proceed to first in man studies. The F3 series represents a proprietary group of compounds with highly potent and selective activity against Aspergillus species and other moulds, which act via a totally novel mechanism.
Others: F2G Limited, an antifungal drug discovery and development company, has announced the completion of a $30 million equity financing round in which two new investors (Advent Life Sciences and Novartis Bioventures) joined the existing syndicate (Sunstone Capital, Merifin Capital, K Nominees, and Astellas Venture Fund).
Dr Raj Parekh of Advent and Dr Anja König of Novartis Venture Funds will both be joining the Board of F2G.
Therapeutic area: Infectious diseases
